| 6.275 0.195 (3.21%) | 06-15 09:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.35 |
1-year : | 9.75 |
| Resists | First : | 7.15 |
Second : | 8.35 |
| Pivot price | 6.12  |
|||
| Supports | First : | 5.74 |
Second : | 4.86 |
| MAs | MA(5) : | 6.19 |
MA(20) : | 5.9 |
| MA(100) : | 5.7 |
MA(250) : | 5.51 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.4 |
D(3) : | 72.1 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 9.39 | Low : | 3.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HBIO ] has closed above bottom band by 46.3%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.69 - 6.73 | 6.73 - 6.75 |
| Low: | 6 - 6.03 | 6.03 - 6.06 |
| Close: | 6.03 - 6.08 | 6.08 - 6.13 |
Harvard Bioscience, Inc. (HBIO) is a global provider of cutting-edge technologies, products, and services crucial for fundamental scientific investigation, drug discovery, and preclinical testing. Serving both domestic and international markets, the company supplies an extensive range of cellular and molecular instruments. This includes precision fluid handling devices like syringe and peristaltic pumps, alongside a variety of tools and accessories for tissue and organ-based laboratory research, such as surgical instruments, infusion systems, and behavioral analysis setups. Their portfolio also encompasses analytical equipment like spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis units, and electroporation/electrofusion instruments. Moreover, Harvard Bioscience specializes in developing and manufacturing advanced scientific measuring instrumentation, featuring sophisticated data acquisition systems with customizable amplifier configurations for cellular analysis, microelectrode array solutions for in vivo recordings, and in vitro systems for extracellular studies, in addition to a full suite of preclinical products. The company markets its offerings through direct sales teams, online channels, catalogs, and authorized distributors. Their diverse customer base includes research scientists within pharmaceutical and biotechnology companies, academic institutions (universities, colleges), hospitals, government laboratories, and contract research organizations. Products are sold under well-known brand names such as Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. Founded in 1901, Harvard Bioscience, Inc. is headquartered in Holliston, Massachusetts.
Fri, 12 Jun 2026
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Fri, 12 Jun 2026
HBIO Stock Price, Quote & Chart - ChartMill
Thu, 11 Jun 2026
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Thu, 11 Jun 2026
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
Thu, 07 May 2026
When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)? - simplywall.st
Mon, 16 Mar 2026
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 45 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 171 (K) |
| EPS | -2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.23 |
| Profit Margin | -11.5 % |
| Operating Margin | -4.6 % |
| Return on Assets (ttm) | 1.7 % |
| Return on Equity (ttm) | -78.7 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 11.07 |
| Sales Per Share | 18.96 |
| EBITDA (p.s.) | 1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -2.83 |
| PEG Ratio | 1.3 |
| Price to Book value | 2.72 |
| Price to Sales | 0.32 |
| Price to Cash Flow | 8.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|